Freedom from chronic lung allograft dysfunction (CLAD) or CLAD-free survival: What's in a name?

Long-term outcomes after lung transplantation (LTx) remain inferior to those of other solid organs, such as heart transplantation. This is largely the result of a high prevalence of chronic lung allograft dysfunction (CLAD), which affects approximately 50% of transplanted patients at 5 years post-transplant.1 Although bronchiolitis obliterans syndrome (BOS) is the major clinical phenotype of CLAD (occurring in 70% of CLAD patients), restrictive allograft syndrome (RAS), the other CLAD phenotype (30%), has shown worse survival after diagnosis.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: EDITORIAL Source Type: research